Morgan Stanley Maintains Overweight on 10x Genomics, Lowers Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant maintains an Overweight rating on 10x Genomics (NASDAQ:TXG) but lowers the price target from $50 to $46.
August 13, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on 10x Genomics but lowers the price target from $50 to $46.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100